Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9P0W8
UPID:
SPAT7_HUMAN
Alternative names:
HSD-3.1; Spermatogenesis-associated protein HSD3
Alternative UPACC:
Q9P0W8; Q5BKY5; Q8WX30; Q96HF3; Q9H0X0; Q9P0W7
Background:
Spermatogenesis-associated protein 7, also known as HSD-3.1, plays a crucial role in the maintenance of photoreceptor cells. It ensures the proper localization of RPGRIP1 and proximal connecting cilium proteins, vital for photoreceptor cell stability and function.
Therapeutic significance:
Linked to Leber congenital amaurosis 3 and Retinitis pigmentosa 94, this protein's understanding could pave the way for innovative treatments for these severe retinal dystrophies.